drugset
drugset / Trial / NCT00585143

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

NCT00585143 ↗

Phase 1 Completed 37 enrolled AstraZeneca
RandomizedParallel-groupOpen-labelTreatment

Summary

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

Timeline

Start
2008-01
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-335 Small molecule 45 mg —
Subject Rosuvastatin Small molecule 10 mg —

Indications

No indication recorded.